CL

Business profile & competitive position

Colgate-Palmolive is classified in the Consumer Defensive sector, specifically Household & Personal Products. It operates through two reporting segments: Oral, Personal and Home Care, which covers toothpaste, toothbrushes, soaps, deodorants, skin health products, cleaners and fabric conditioners; and Hill’s Pet Nutrition, which produces specialty dog and cat foods. Its products are sold in over 200 countries and territories through retailers, wholesalers, e-commerce platforms, veterinarians and some direct-to-consumer channels.

In 2025, segment revenue weights were: Oral Care 44% of worldwide net sales, Personal Care 17%, Home Care 16%, and Hill’s Pet Nutrition 23%. That sales concentration highlights Oral Care as the single largest profit engine, while pet nutrition is nearly as large as the combined Home Care business. Walmart and its affiliates represented approximately 11% of 2025 net sales, and no other customer exceeded 10%, a degree of channel concentration that matters for pricing power discussions.

Profitability figures are mixed when used to judge a competitive moat. Net margin is 9.7%, which is healthy but not extraordinary for a branded consumer staples company. By contrast, ROE is reported at 631.1%. With a net margin below 10%, a 631.1% ROE cannot be explained by operating profitability alone; it points to an exceptionally small equity base, usually associated with a leveraged balance sheet and/or significant capital returns such as share buybacks rather than purely a widening operating moat. As of the latest snapshot, the company employed roughly 33,600 people across more than 100 countries, with over 84% located outside the United States. That global footprint is a real scale advantage, but investors should treat the headline ROE as a balance-sheet efficiency signal more than evidence of dominant pricing power.

Financial posture

Colgate-Palmolive currently carries a market capitalization of $70.8B and trades at a trailing P/E of 34.8, well above the multiples typical of many large-cap consumer staples. At the snapshot date, the price sat at $88.5, essentially on top of the 50-day EMA of $88.32. The valuation therefore embeds a premium for stability rather than deep-value compression: investors are paying 34.8x earnings for a company converting 9.7% of each sales dollar into bottom-line profit.

The 631.1% ROE amplifies the financial-engineering profile from the prior section. Because ROE equals net income divided by shareholders’ equity, a number above 600% is consistent with a very low equity denominator, potentially driven by leverage or accumulated buybacks. The beta is 0.32, underscoring the stock’s low sensitivity to broader market movements and reinforcing its defensive classification. No debt figure is provided in this snapshot, so a full assessment of financial risk would require balance-sheet detail, but the combination of a high P/E, a low beta and an extreme ROE describes a leveraged, low-volatility consumer franchise priced for consistency.

Strategic priorities & outlook

Colgate-Palmolive’s most recent 10-K filing summarizes its operating priorities as follows:

• Drive organic sales growth and deliver consistent, compounded earnings-per-share growth.
• Achieve operational efficiencies while growing free cash flow and using the balance sheet efficiently.
• Leverage global brand reach, science-based innovation, an agile supply chain, and best-in-class omni-channel demand generation.
• Build capabilities in data, analytics and artificial intelligence and evolve a high-impact, inclusive culture.

Those priorities align closely with the financial profile already described: growth balanced with cost discipline and balance-sheet efficiency. The firm also calls out specific execution risks and structural facts: it operates in over 200 countries and territories, with more than 84% of its workforce outside the United States. Walmart accounted for about 11% of 2025 net sales, making the retailer relationship strategically important. The 2025 segment split—Oral Care 44%, Personal Care 17%, Home Care 16%, Pet Nutrition 23%—shows where management’s innovation and marketing dollars must be allocated if it is to meet its organic-growth and EPS-compounding goals.

Macro & geopolitical exposure

As a Household & Personal Products company, Colgate-Palmolive is exposed to the macro factors that routinely affect branded consumer staples. Input costs are one: resins, petrochemicals, palm oil derivatives, agricultural commodities used in pet food, packaging materials and freight energy all feed directly into gross margin. With a net margin of 9.7%, any sustained inflation in those inputs puts pressure on profitability unless pricing power fully offsets it.

Because roughly 84% of employees are outside the United States and products are marketed in over 200 countries, foreign-exchange translation is a recurring risk. A stronger U.S. dollar compresses reported overseas earnings, while a weaker dollar provides a tailwind. Trade policy and tariffs can alter sourcing costs and retail pricing strategies. Regulatory risk is also inherent in the industry: product ingredients, labeling claims, sustainability mandates, packaging-waste rules and advertising standards vary by market and can force reformulation or packaging changes. The 11% customer concentration with Walmart adds another macro-adjacent sensitivity—changes in retailer terms, private-label competition or shelf resets can materially affect volume. Interest-rate cycles matter less for demand (beta is 0.32), but they can affect the relative attractiveness of a 34.8 P/E stock to income and defensive investors.

Recent developments

Headlines over the first ten days of October 2026 clustered around dividend durability and peer comparisons rather than operational news about Colgate-Palmolive specifically:

• October 10, 2026 (fool.com): “Want to Retire on Dividends? Here Are 4 Stocks to Buy Now and Never Sell.”
• October 6, 2026 (zacks.com): “Colgate vs. Clorox: Which Consumer Staples Giant Holds the Edge?”
• October 6, 2026 (247wallst.com): “Bond Yields Are Soaring: These 5 Fortress Dividend Stocks Offer Shelter for Income Investors.”
• October 3, 2026 (247wallst.com): A retrospective on Ronald Read’s blue-chip dividend portfolio, noting his accumulation of dividend-paying stocks over five decades.

None of these articles report fresh financial results or strategic changes, but they confirm the prevailing narrative being applied to CL ahead of its October 30, 2026 earnings report: it is being bucketed with “fortress dividend” and defensive equity names in a higher-yield environment. The Zacks comparison with Clorox is the only item that directly frames Colgate-Palmolive against a sector peer, suggesting the stock is being evaluated on relative staples quality rather than as a standalone growth story.

Earnings behavior & post-earnings drift

Colgate-Palmolive’s earnings record is unusually consistent. Over the last eight reported quarters, it beat consensus EPS every time, for a beat rate of 8/8 (100%). The average earnings surprise across those quarters was 3.3%. The average 5-day price move after those reports was +2.32%, classified as upward drift.

The most recent four quarters illustrate how those beats have translated into price action:

• July 31, 2026: EPS of $0.99 vs. $0.947 estimate (+4.5% surprise). The next day the stock fell 1.56%, but it gained 2.16% over the following five sessions.
• May 1, 2026: EPS of $0.97 vs. $0.943 estimate (+2.9% surprise). The next day it dropped 2.17%, while the five-day drift was just +0.33%.
• January 30, 2026: EPS of $0.95 vs. $0.912 estimate (+4.2% surprise). The stock rose 1.77% the next day and 4.56% over the next five sessions.
• October 31, 2025: EPS of $0.91 vs. $0.889 estimate (+2.4% surprise). The next day it fell 2.69%, yet the five-day drift was +2.22%.

The pattern is consistent: even when the immediate next-day reaction to an earnings beat was negative, the stock’s five-day trajectory was positive in three of the last four quarters and averaged +2.32% across the broader eight-quarter window. The next scheduled report is October 30, 2026, before the market open, with an analyst consensus EPS estimate of $0.929. The current RSI is 55.6, near neutral, and price sits essentially at the 50-day EMA of $88.32.

For a deeper dive into rating changes, consensus revisions, risk-factor assessments, and the current institutional positioning around Colgate-Palmolive, consult the platform's full institutional verdict for CL.